These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

5159 related articles for article (PubMed ID: 4152218)

  • 1. Effects of 2,2'(methylenediimino)bis-1,3,4-thiadiazole (NSC-143019) on tumor growth and immune responses in mice.
    Matsumoto T; Ootsu K; Okada Y
    Cancer Chemother Rep; 1974; 58(3):331-44. PubMed ID: 4152218
    [No Abstract]   [Full Text] [Related]  

  • 2. Antitumor activity of cyclocytidine in a variety of tumors.
    Hoshi A; Kanzawa F; Kuretani K
    Gan; 1972 Jun; 63(3):353-60. PubMed ID: 5072834
    [No Abstract]   [Full Text] [Related]  

  • 3. Dextran derivatives in single and combination chemotherapy against transplantable mouse ascites and solid tumors.
    Suzuki M; Mikami T; Kadowaki M; Matsumoto T; Suzuki S
    Cancer Res; 1977 Sep; 37(9):3448-54. PubMed ID: 69495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of different doses of methotrexate (NSC-740), cytosine arabinoside (NSC-63878), and cyclophosphamide (NSC-26271) on drug resistance in mice with L1210 leukemia.
    Schmid FA; Hutchison DJ
    Cancer Chemother Rep; 1972 Aug; 56(4):473-81. PubMed ID: 5081590
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. IX.
    Kline I; Gang M; Tyrer DD; Venditti JM; Artis EW; Goldin A
    Cancer Chemother Rep 2; 1971 Apr; 2(1):65-133. PubMed ID: 5565539
    [No Abstract]   [Full Text] [Related]  

  • 6. Characteristics and response to certain cancer chemotherapeutic agents of an acute lymphocytic leukemia arising in a BALB-c times DBA-2F1 mouse.
    Yancey ST; Bleyer WA
    Cancer Res; 1974 Aug; 34(8):1866-9. PubMed ID: 4526157
    [No Abstract]   [Full Text] [Related]  

  • 7. Value of cytosine arabinoside (NSC-63878) plus 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) therapy in advanced murine L1210 leukemia and enhancement of the combination with sequential doses of methotrexate (NSC-740) or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
    Kline I; Woodman RJ; Gang M; Cysyk RL; Venditti JM
    Cancer Chemother Rep; 1973; 57(3):291-8. PubMed ID: 4751255
    [No Abstract]   [Full Text] [Related]  

  • 8. Synergistic effects of bis(3-methylsulfonyloxypropyl)-amine toluenesulfonate (864-T) with 6-mercaptopurine and other antitumor agents.
    Imamura H; Ikegami K; Okumoto T
    Gan; 1973 Oct; 64(5):427-31. PubMed ID: 4358730
    [No Abstract]   [Full Text] [Related]  

  • 9. [Antitumor chemotherapy. Considerations on the potential role of immunity].
    Mihich E
    Pathol Biol; 1967 Feb; 15(3):209-14. PubMed ID: 4860732
    [No Abstract]   [Full Text] [Related]  

  • 10. Increased lifespan using the priming dose schedule design in carbazilquinone (NSC-134679) treatment of mouse leukemia L1210.
    Straus MJ; Goldin A
    Cancer Chemother Rep; 1972 Feb; 56(1):19-23. PubMed ID: 5030804
    [No Abstract]   [Full Text] [Related]  

  • 11. Selection for high immunogenicity in drug-resistant sublines of murine lymphomas demonstrated by plaque assay.
    Fuji H; Mihich E
    Cancer Res; 1975 Apr; 35(4):946-52. PubMed ID: 1090366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The enhanced therapeutic effect of cis-platinum (II) diamminodichloride against L1210 leukemia when combined with cyclophosphamide or 1,2-bis(3,5-dioxopiperazine-1-yl)propane or several other antitumor agents.
    Woodman RJ; Sirica AE; Gang M; Kline I; Venditti JM
    Chemotherapy; 1973; 18(3):169-83. PubMed ID: 4119363
    [No Abstract]   [Full Text] [Related]  

  • 13. Chemotherapy of advanced L1210 leukemia with platinum compounds in combination with other antitumor agents.
    Gale GR; Atkins LM; Meischen SJ; Smith AB; Walker EM
    Cancer Treat Rep; 1977; 61(3):445-50. PubMed ID: 872142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-tumor sensitivity matching procedure using diffusion chambers in vivo.
    Cain BF; Calveley SB; Boreham BA; West C; Price NA; Walker DJ; Churchouse MJ
    Cancer Chemother Rep; 1974; 58(2):189-205. PubMed ID: 4857364
    [No Abstract]   [Full Text] [Related]  

  • 15. Antigenic changes associated with resistance to methotrexate and 6-mercaptopurine in L1210 ascites lymphoma.
    Calman NS; Eng B; Slater LM; Wallerstein H
    J Natl Cancer Inst; 1974 Mar; 52(3):997-8. PubMed ID: 4826575
    [No Abstract]   [Full Text] [Related]  

  • 16. Antitumor activity of a novel synthetic polyamine analogue, N,N'-bis-[3-(ethylamino)-propyl]-1-7-heptane diamine: potentiation by polyamine oxidase inhibitors.
    Prakash NJ; Bowlin TL; Edwards ML; Sunkara PS; Sjoerdsma A
    Anticancer Res; 1990; 10(5A):1281-7. PubMed ID: 2241104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy studies in an animal tumor spectrum. II. Sensitivity of tumors to fourteen antitumor chemicals.
    Tarnowski GS; Schmid FA; Cappuccino JG; Stock CC
    Cancer Res; 1966 Mar; 26(3 Pt 2):181-206. PubMed ID: 4223040
    [No Abstract]   [Full Text] [Related]  

  • 18. The synergistic anti-neoplastic activity of combinations of mitomycins with either 6-thioguanine or 5-fluorouracil.
    Sartorelli AC; Booth BA
    Cancer Res; 1965 Oct; 25(9):1393-400. PubMed ID: 5861069
    [No Abstract]   [Full Text] [Related]  

  • 19. Sensitivity of Nakahara-Fukuoka sarcoma to antitumor agents, especially to purine analogs.
    Hoshi A; Kumagai K; Kanzawa F; Kuretani K
    Gan; 1969 Feb; 60(1):115-7. PubMed ID: 4976551
    [No Abstract]   [Full Text] [Related]  

  • 20. Radiosensitivity of drug-resistant L1210 leukemia.
    Johnson RE
    Cancer Res; 1967 Feb; 27(2):251-4. PubMed ID: 6018559
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 258.